Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone

Keyphrases

• Luteinizing Hormone 100%
• Subcutaneous Treatment 100%
• Buserelin 100%
• Precocious Puberty 100%
• Long-acting Analog 100%
• Intranasal Treatment 100%
• Gonadotropins 66%
• Growth Velocity 66%
• Puberty 33%
• Testosterone 33%
• Treatment Phase 33%
• Behavioral Improvement 33%
• Tanner Stage 33%
• Safety Self-efficacy 33%
• Clinical Improvement 33%
• Pituitary Gonadotropins 33%
• D-Ser 33%
• Pubertal Development 33%
• Intranasal 33%
• Bone Maturation 33%
• 17-estradiol 33%
• LHRH Agonist 33%
• Idiopathic Precocious Puberty 33%
• Skeletal Maturity 33%
• Accelerated Growth 33%
• Chronic Administration 33%
• Transient Acceleration 33%
• Sexual Precocity 33%
• Unwanted Effects 33%
• Optimal Dose 33%
• Therapy Discontinuation 33%
• Withdrawal Bleeding 33%
• Parenteral Treatment 33%
• Sex Steroids 33%
• Gonadotropin Secretion 33%

Medicine and Dentistry

• Gonadorelin 100%
• Precocious Puberty 100%
• Buserelin 75%
• Growth Rate 50%
• Bone Maturation 50%
• Gonadotropin 50%
• Gonadorelin Agonist 25%
• Sex Hormone 25%
• Parenteral Drug Administration 25%
• Withdrawal Bleeding 25%
• Optimal Drug Dose 25%
• Chronic Drug Administration 25%
• Gonadotropin Release 25%
• Diethylstilbestrol 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Gonadorelin 100%
• Precocious Puberty 100%
• Gonadotropin 75%
• Buserelin 75%
• Gonadorelin Agonist 25%
• Sex Hormone 25%
• Withdrawal Bleeding 25%
• Diethylstilbestrol 25%